What is the clinical evidence from this study?

Study design: RCT. Population: Anthracycline-induced cardiomyopathy (n=50). Intervention: Carvedilol vs. Placebo. Primary outcome: Mean left ventricular ejection fraction at 6 months.

What does this research mean for the field?

Prophylactic carvedilol preserves left ventricular systolic and diastolic function, preventing the decline in ejection fraction seen with anthracycline chemotherapy. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the cardioprotective efficacy of prophylactic carvedilol in preventing left ventricular cardiomyopathy in patients undergoing anthracycline chemotherapy.

September 24, 2026Journal of the American College of CardiologyOpen Access

Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy

Q: What are the key findings of this study?

Prophylactic carvedilol preserved mean left ventricular ejection fraction at 6 months compared to control (69.7% vs 52.3%) in patients receiving anthracycline therapy.

View Full Paper

Ask AI

Bookmark

Key result

Prophylactic carvedilol maintains ~17% higher LVEF vs control at 6 months during anthracycline therapy.

n=50

Why the study?

There is no placebo-controlled clinical trial concerning prophylactic carvedilol use in preventing anthracycline-induced cardiomyopathy.

Population

25 patients planned for anthracycline therapy

Comparison

Carvedilol 12.5 mg once daily vs placebo

Design

Randomized placebo-controlled clinical trial

Follow-up

6 months

Authors

NKNihat KalayInterventional Cardiology EBEmrullah BaşarInstitute of Cardiology İÖİbrahіm ÖzdoğruIstanbul Eye Hospital

Discussion

Member takes

Implication

May support carvedilol prophylaxis in anthracycline recipients; leaves open confirmation in larger trials before practice change.

Key Points

To evaluate the cardioprotective efficacy of prophylactic carvedilol in preventing left ventricular cardiomyopathy in patients undergoing anthracycline chemotherapy.
Randomized, placebo-controlled trial assigning patients scheduled for anthracycline chemotherapy to carvedilol or placebo groups (N=25 per group).
Administered oral carvedilol at 12.5 mg once daily for 6 months during chemotherapy treatment.
Assessed cardiac function with echocardiography before and after 6 months of chemotherapy, measuring left ventricular ejection fraction, chamber dimensions, and Doppler flow velocities.
Mean left ventricular ejection fraction remained stable in the carvedilol group (70.5% baseline vs. 69.7% at follow-up, p=0.3) but dropped significantly in the control group (68.9% baseline vs. 52.3% at follow-up, p<0.001).
Ejection fraction fell below 50% in 1 patient in the carvedilol arm compared with 5 patients in the control arm; 1 patient died in the carvedilol group versus 4 in the control group.
Left ventricular systolic and diastolic dimensions increased significantly only in controls, who also exhibited significant reductions in Doppler E velocities and E/A ratios.

Study Design

Type

RCT (n=50)

Blinding

placebo-controlled

Randomization

randomized

PICO

Population

50 patients planned for anthracycline therapy randomized to carvedilol or placebo and followed for 6 months.

Intervention / Comparator

Carvedilol vs Placebo (12.5 mg once-daily oral)

Primary Outcome

Mean left ventricular ejection fraction at 6 months

Main Result

Absolute Event Rate: 69.7% vs 52.3%

Cite This Study

Kalay et al. (2006) conducted an RCT in Anthracycline-induced cardiomyopathy (n=50). Carvedilol vs. Placebo was evaluated on Mean left ventricular ejection fraction at 6 months. Prophylactic carvedilol preserved mean left ventricular ejection fraction at 6 months compared to control (69.7% vs 52.3%) in patients receiving anthracycline therapy.

synapsesocial.com/papers/6ab4ea5a9b195e3785fe8e9e https://doi.org/10.1016/j.jacc.2006.07.052

View Full Paper

Ask AI

Bookmark

Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Study Design

PICO

Main Result

Cite This Study

Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Study Design

PICO

Main Result

Cite This Study

Also Consider

Also Consider